CervoMed Inc. - 8-K Filing

CervoMed announces pharmacokinetic results for new neflamapimod tablet formulation and FDA removal of drug exposure limit (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CRVO

Read the full article at SEC EDGAR

More Regulatory news